Anacor (ANAC) Completes Enrollment in Two Tavaborole Phase 3s

Anacor Pharmaceuticals (Nasdaq: ANAC) has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Gray Media closes $750M note offering to refinance higher-rate debt
• enVVeno Medical (NVNO) files $100M mixed shelf